TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01375322

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine+Benazepril
Description: Amlodipine besylate 5 mg + Benazepril hydrochloride 10 mg, daily use and forced titrate till 16-week end

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valsartan+Hydrochlorothiazide
Description: Valsartan 80 mg + Hydrochlorothiazide 12.5 mg, daily use and forced titrate till 16-week end
Study: NCT03329027

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vibrating Capsule
Description: Patients will receive vibrating capsule for 8 weeks of treatment (5 capsules/week)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vibrating Capsule
Description: Patients will receive vibrating capsule for 8 weeks of treatment (5 capsules/week)

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham capsule
Description: Patients will receive vibrating capsule for 8 weeks of treatment (5 capsules/week)
Study: NCT04223440

Intervention type: OTHER
Group type: OTHER
Intervention: MRI
Description: MRI on both shoulder

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRI
Description: MRI on both shoulder

Intervention type: OTHER
Group type: OTHER
Intervention: ultrasonographic explorations
Description: ultrasound and elastography explorations on both shoulder

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ultrasonographic explorations
Description: ultrasound and elastography explorations on both shoulder
Study: NCT05757011

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: pre-sacral nerve block (bupivacaine injection into both uterosacral ligaments at the end of laparoscopic hysterectomy.
Description: pre-sacral nerve block (bupivacaine injection into both uterosacral ligaments at the end of laparoscopic hysterectomy.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: pre-sacral nerve block (bupivacaine injection into both uterosacral ligaments at the end of laparoscopic hysterectomy.
Description: pre-sacral nerve block (bupivacaine injection into both uterosacral ligaments at the end of laparoscopic hysterectomy.
Study: NCT04480398

Intervention type: DRUG
Intervention: Guduchi Ghan Vati
Description: Guduchi Ghan Vati is an Ayuvedic classical preparation which is prepared from aqueous of extract of Tinospora cordifolia.
Study: NCT00497796

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: maribavir
Description: 100mg twice a day for 14 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ganciclovir
Description: 1000mg three times per day for 14 weeks.
Study: NCT01074554

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antibiotic Regimen
Description: Levaquin 750 mg loading on day 1, then 500 mg po QD Ethambutol 15-25 mg/kg for a maximum of 1200mg QD Azithromycin 500mg on day 1, then 250 mg po QD Rifampin 5-10 mg/kg for a maximum of 300mg po QD All four drugs are given concomitanly

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Regimen
Description: lactose control tablets; one for each antibiotic with equivalent pills
Study: NCT03970564

Intervention type: DIAGNOSTIC_TEST
Intervention: Neck ultrasound guide lymph node sampling
Description: Neck ultrasound done first and lymph nodes larger than 5 mm that are technically feasible are sampled using fine needle aspiration and/or core needle biopsy
Study: NCT01976130

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bronchoscopy
Study: NCT01611389

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prolonging atrioventricular (AV) delay.
Description: Prolonging atrioventricular (AV) delay to maximum 350 ms.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard atrioventricular (AV) delay.
Description: Standard atrioventricular (AV) delay - approximately 180/140 ms depending on heart rate.
Study: NCT04418388

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBK-1801
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBK-1801
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBK-1801
Description: Administered orally
Study: NCT02780336

Intervention type: OTHER
Intervention: No intervention.
Description: Participants will complete questionnaires and interviews as well as have a neurological exam that will be video recorded. For this exam they will do simple movements (like looking at the camera, squeezing your eyes closed, moving your head, and writing).

Intervention type: OTHER
Intervention: No intervention.
Description: Participants will complete questionnaires and interviews as well as have a neurological exam that will be video recorded. For this exam they will do simple movements (like looking at the camera, squeezing your eyes closed, moving your head, and writing).

Intervention type: OTHER
Intervention: No intervention.
Description: Participants will complete questionnaires and interviews as well as have a neurological exam that will be video recorded. For this exam they will do simple movements (like looking at the camera, squeezing your eyes closed, moving your head, and writing).
Study: NCT00220337

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lacosamide
Description: Lacosamide film-coated tablets; two times per day; up to 400 mg/day for 2.75 years
Study: NCT01624376

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DLX105
Description: 10mg DLX105/injection injected into the fistula over a treatment period of 4 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo injections are administered over the treatment period of 4 weeks.
Study: NCT03393650

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise + Placebo group
Description: 1/2 of the subject will follow a mixed power training: 4 power exercises + 6 functional exercises combined to a placebo

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise + Protein group
Description: 1/2 of the subject will receive 30 g/ d of protein (leucine+ vitD; divided in three equal doses: morning, afternoon and evening) + will follow a mixed power training: 4 power exercises + 6 functional exercises.
Study: NCT03661528

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: andexanet alfa
Description: Andexanet alfa is a recombinant version of human FXa

Intervention type: DRUG
Group type: OTHER
Intervention: Usual Care
Description: Usual care will consist of any treatment(s) (including no treatment) other than andexanet alfa administered within 3 hours post-randomization that the Investigator and/or other treating physicians consider to be appropriate.
Study: NCT04860219

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lactoferrin
Description: 7 successive days treatment of Lactoferrin started within day 0 of COVID-19 diagnosis by RT-PCR

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lactoferrin
Description: 7 successive days treatment of Lactoferrin started within day 0 of COVID-19 diagnosis by RT-PCR
Study: NCT03889756

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine infusion
Description: The dose of ketamine established in prior research (0.5 mg/kg over 40 minutes) will be used in this study to minimize risks. The maximum total single dose allowed in this study will be 40mg, corresponding to a weight of 80kg.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Midazolam infusion
Description: The weight-based midazolam dosing established in prior ketamine trials in adults (0.045mg/kg) will be used to minimize risks, as this is considered a very low dose compared to the sedation literature. The maximum total dose allowed in this study will be 3.6mg per infusion, corresponding to a weight of 80kg.
Study: NCT04452734

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Platelet Rich Plasma (PRP)
Description: PRP was prepared by withdrawing 8-10 ml of patients own blood (IV from antecubiodal area and collected in a vacuum tube coated with anticoagulant (Na citrate). For activation 1 ml of calcium chloride was added to Platelet Rich Plasma. This layer of approximately 2 ml of PRP was then taken into the residual bone cavity along with gel sponge to stimulate regeneration in wound healing after surgical extraction of mandibular third molar tooth followed by sutures

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical Extraction
Description: Surgical extraction procedure under Local anesthesia on dental chair, followed by spongstone (gel sponge) and suture placement.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical Extraction
Description: Surgical extraction procedure under Local anesthesia on dental chair, followed by spongstone (gel sponge) and suture placement.
Study: NCT00643578

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: formoterol
Description: a single dose of 24 mcg of formoterol delivered by dry powder inhaler (Twisthaler)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: formoterol
Description: a single dose of 12 mcg of formoterol delivered by dry powder inhaler (Twisthaler)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dry Powder Inhaler (Twisthaler)
Description: subjects inhaled deeply and forcefully and held their breath for 10 seconds for each dose

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dry Powder Inhaler (Twisthaler)
Description: subjects inhaled deeply and forcefully and held their breath for 10 seconds for each dose
Study: NCT04540640

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kidney perfusion pump
Description: The pulsatile perfusion device will circulate room temperature oxygenated perfusion solution through the donor kidney ex vivo.
Study: NCT03236181

Intervention type: OTHER
Group type: OTHER
Intervention: SFA
Description: High saturated fatty acid/SFA oil source

Intervention type: OTHER
Group type: OTHER
Intervention: MUFA
Description: High monounsaturated fatty acid/MUFA oil source

Intervention type: OTHER
Group type: OTHER
Intervention: PUFA
Description: High polyunsaturated fatty acid (linoleic)/PUFA oil source

Intervention type: OTHER
Group type: OTHER
Intervention: LCn3
Description: High polyunsaturated fatty acid (omega-3)/LCn3 oil source
Study: NCT03683407

Intervention type: OTHER
Intervention: Next-Genernation Sequence
Description: Tumor Mutation burden will be evaluated using NGS after 2-cycle chemotherapy, 4-cycle chemotherapy, or at progressive disease
Study: NCT00984295

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live
Description: A single 0.5 mL subcutaneous injection at Day 0

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live
Description: A single 0.5 mL subcutaneous injection at Day 0

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Comparator: Tripedia
Description: A single 0.5 mL intramuscular injection (at Day 0 or Day 42)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Comparator: Tripedia
Description: A single 0.5 mL intramuscular injection (at Day 0 or Day 42)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: Tripedia
Description: A single 0.5 mL intramuscular injection (at Day 0 or Day 42)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Comparator: Comvax
Description: A single 0.5 mL intramuscular injection (at Day 0 or Day 42)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Comparator: Comvax
Description: A single 0.5 mL intramuscular injection (at Day 0 or Day 42)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: Comvax
Description: A single 0.5 mL intramuscular injection (at Day 0 or Day 42)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: Varivax
Description: A single 0.5 mL subcutaneous injection at Day 0

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: M-M-R II
Description: A single 0.5 mL subcutaneous injection at Day 0
Study: NCT01737190

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PEEP guided by Esophageal pressure + Recruitment maneuver
Description: Upon patient recruitment Esophageal balloon will be inserted and esophageal / pleural pressure will be measured. Thereafter, Inspiratory pressures and PEEP will be adjusted according to well established criteria. Inspiratory pressure and PEEP will be adjusted to achieve the best lung compliance possible while not exceeding transpulmonary end Inspiratory pressure of 25 to 30 cm H2O, and at the same time maintaining a positive transpulmonary end expiarory pressure of not more than 5 cm H2O.~A recruitment maneuver with application of 40 cm H2O for up to 40 seconds will be performed.
Study: NCT04538170

Intervention type: BEHAVIORAL
Intervention: pain after surgery

Intervention type: BEHAVIORAL
Intervention: pain after surgery
Study: NCT01072110

Intervention type: PROCEDURE
Intervention: Colonoscopy
Description: Patients will undergo colonoscopy for evaluation of their symptoms.

Intervention type: PROCEDURE
Intervention: Confocal Laser Endomicroscopy
Description: Patients will undergo CLE during their endoscopy. Findings will be compared to group 1.
Study: NCT03605238

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Corticosteroids & tanCART19/20
Description: Twelve days of high-dose IV methylprednisolone (1000mg×3 days, 500mg×3 days, 240mg×3 days, 120mg×3 days) before anti-CD19/20 CAR T cells infusion. The dose is 1E5\~2E6 anti-CD19/20-CAR positive T cells. The cells infusion process may last for 30 min.
Study: NCT03185065

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amantadine
Description: 100 mg of amantadine increased to 200 mg of amantadine, if tolerated

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amantadine
Description: 100 mg of amantadine increased to 200 mg of amantadine, if tolerated

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amantadine
Description: 100 mg of amantadine increased to 200 mg of amantadine, if tolerated

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amantadine
Description: 100 mg of amantadine increased to 200 mg of amantadine, if tolerated

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modafinil
Description: 100 mg of modafinil increased to 200 mg of modafinil, if tolerated

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modafinil
Description: 100 mg of modafinil increased to 200 mg of modafinil, if tolerated

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modafinil
Description: 100 mg of modafinil increased to 200 mg of modafinil, if tolerated

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modafinil
Description: 100 mg of modafinil increased to 200 mg of modafinil, if tolerated

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Description: 5 mg of methylphenidate uptitrated to max of 20 mg of methylphenidate, if tolerated

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Description: 5 mg of methylphenidate uptitrated to max of 20 mg of methylphenidate, if tolerated

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Description: 5 mg of methylphenidate uptitrated to max of 20 mg of methylphenidate, if tolerated

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Description: 5 mg of methylphenidate uptitrated to max of 20 mg of methylphenidate, if tolerated

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebos
Description: 1 placebo capsule increased to max of 2 capsules twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebos
Description: 1 placebo capsule increased to max of 2 capsules twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebos
Description: 1 placebo capsule increased to max of 2 capsules twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebos
Description: 1 placebo capsule increased to max of 2 capsules twice daily
Study: NCT02096419

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel dose adjustment
Description: Patients in the interventional arm will receive clopidogrel dose adjustment to maintain optimal platelet reactivity determined by Multiplate function analyzer (19-46U).~They will undergo platelet function testing on day 1,2,3,7,30 and month 2,3,6,9 and 12.~On first two measurements patients will receive up to 2 additional clopidogrel loading doses (600 mg) and put on 150 mg and 75 mg a day if platelet reactivity \>18U and \<18U, respectively. Maintenance dose will be determined on following measurements - increased by 75 mg if \>46U; not changed if 19-46U; decreased by 75 mg if \<19U. Minimal dose - 75 mg; maximal dose 300 mg (for patients \>70 years 150 mg)
Study: NCT00728949

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMC-A12 (cixutumumab)
Description: 10 mg/kg I.V.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: IMC-A12 (cixutumumab)
Description: 10 mg/kg I.V.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tamoxifen
Description: Daily 20 mg, oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anastrozole
Description: Daily 1 mg, oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole
Description: Daily 2.5 mg, oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exemestane
Description: Daily 25 mg, oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fulvestrant
Description: Monthly 250 mg, intramuscularly
Study: NCT03408626

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Papain-based Chemo-mechanical caries removal agent
Description: Birx 3000 and the exclusive Encapsulating Buffer Emulsifier (EBE) technology claim it has effective and selective proteolytic action to remove collagen fiber in the carious tissue. It has an antibacterial and antifungal power, thus it has an antiseptic power at the tissue level .furthermore, this gel does not contain chloramines in its formula, which enhances its toxicological safety feature.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Papain-based Chemo-mechanical caries removal agent
Description: Birx 3000 and the exclusive Encapsulating Buffer Emulsifier (EBE) technology claim it has effective and selective proteolytic action to remove collagen fiber in the carious tissue. It has an antibacterial and antifungal power, thus it has an antiseptic power at the tissue level .furthermore, this gel does not contain chloramines in its formula, which enhances its toxicological safety feature.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: conventional rotary
Description: traditional rotary method

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: conventional rotary
Description: traditional rotary method
Study: NCT04978532

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Guided Imagery
Description: The children in the guided imagery group listened to a voice recording named 'Stroll in the Forest' before and during venipuncture. One minute before venipuncture, children wore an earphone and voice recording started. Children closed their eyes, imagined the text content, and focused on the voice recording while listening to the voice. It is a voice recording that helps the children in the guided imagery group to imagine that they are strolling in a forest and guides them.

Intervention type: OTHER
Group type: OTHER
Intervention: Control Group
Description: No intervention was made in the children.
Study: NCT02433678

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dapagliflozin
Description: SGLT-2 inhibitor for the treatment of type 2 diabetes

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04605107

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epifasi: Human chorionic gonadotrophin
Description: IM Injection of 1 ampoule contains 5000 I.U. of Human chorionic gonadotrophin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregnyl: Human chorionic gonadotrophin
Description: IM Injection of 1 ampoule contains 5000 I.U. of Human chorionic gonadotrophin
Study: NCT04084483

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: K-161
Description: K-161 alternate dosage

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: K-161
Description: K-161 alternate dosage

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: K-161
Description: K-161 alternate dosage

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Vehicle)
Description: Placebo solution
Study: NCT02827409

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Short Delay Cord Clamping
Description: Delay cord clamping will occur for up to 1 minute. Subject will be placed on mother's abdomen for warmth and stimulation. If the subject is depressed they will be transferred to the radiant warmer for resuscitation.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Extended Delay Cord Clamping
Description: Extended delay cord clamping will occur for at least 5 minutes and will continue until the subjects begins breathing and/or the cord stops pulsating. Subject will be placed on mother's abdomen for warmth and stimulation. If the subject is depressed they will be transferred to the LifeStart bed for resuscitation adjacent to the mother's bedside.
Study: NCT03797664

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CDX-6114
Description: CDX-6114 will be administered as a single, oral dose solution at dose levels of 7.5, 15.0 and 22.5g

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Phosphate Buffer Diluent oral solution
Study: NCT00726960

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aprepitant
Description: Oral, 125 mg once daily for one week

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pseudo-placebo - buprenorphine
Description: Randomized to receive either 8 mg sublingual tablets or 0.4 mg sublingual tablets
Study: NCT00982553

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: 800mg once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: 800mg once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltegravir
Description: 400mg twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltegravir
Description: 400mg twice daily
Study: NCT01362998

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Preservative free morphine
Description: 3mg given epidurally during the Cesarean section.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: An infusion of epidural fentanyl started during the Cesarean section. It will be given on a patient controlled analgesia basis, with a basal rate of 60 micrograms, a demand dose of 16 micrograms, and a lockout of 15 mins.